* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 23,303 · FY2023 14,346 · FY2024 5,755 — 3-yr total 43,404
International Medical Technologies JSC (სს საერთაშორისო სამედიცინო ტექნოლოგიები, imt.ge) distributes medical devices to Georgian hospitals, specialising in interventional cardiology, interventional radiology, cardiac surgery and laboratory equipment. It represents around twenty manufacturers, among them Abbott, Boston Scientific, Medtronic, Terumo, C.R. Bard, Biotronik, Edwards Lifesciences, Johnson & Johnson, St. Jude Medical and Siemens. Based at 1 Ch. Amirejibi Highway, Block A, Vake-Saburtalo, Tbilisi. It carried no sector and no description on this record. Its declared NACE is 46460, wholesale of pharmaceutical goods, which does not match what it sells and is why it read as a pharma wholesaler. The P&L is a pure trading book: cost of sales is 84% of revenue, personnel expense ₾0.7m and depreciation ₾2,159, so there is no clinical or manufacturing operation behind it. Revenue falls from ₾84.2m (FY2022) to ₾72.7m (FY2023) to ₾39.6m (FY2024) with gross margin at 21.2%, 20.5% and 16.5% and EBITDA at ₾17.1m, ₾14.0m and ₾5.7m. Margins in the high teens are thin for devices and reflect high-ticket implant supply priced into public tenders; the revenue halving across two years is a real contraction and warrants a look at whether tender awards moved to a competitor.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 41,149 | 60,710 | 53,222 | 79,758 | 84,217 | 72,706 | 39,590 | -0.6% | |
| Total COGS | 31,806 | 48,959 | 40,987 | 58,690 | 66,401 | 57,825 | 33,071 | +0.7% |
| Gross Profit | 9,344 | 11,751 | 12,236 | 21,068 | 17,817 | 14,881 | 6,519 | -5.8% |
| Gross Margin | 22.7% | 19.4% | 23.0% | 26.4% | 21.2% | 20.5% | 16.5% | |
| 1,492 | 2,076 | 2,386 | 2,227 | 716 | 881 | 811 | -9.7% | |
| EBITDA | 7,851 | 9,674 | 9,850 | 18,841 | 17,101 | 14,000 | 5,708 | -5.2% |
| EBITDA Margin | 19.1% | 15.9% | 18.5% | 23.6% | 20.3% | 19.3% | 14.4% | |
| Total D&A | 1 | 3 | 4 | 5 | 5 | 4 | 2 | +11.0% |
| EBIT / Operating Income | 7,850 | 9,671 | 9,845 | 18,836 | 17,096 | 13,997 | 5,706 | -5.2% |
| Total Interest Income | 0 | 0 | 0 | 0 | 14 | 0 | 0 | |
| Total Interest Expense | 104 | 312 | 218 | 21 | 110 | 187 | 107 | +0.5% |
| 400 | 364 | 440 | 622 | 273 | 490 | 312 | -4.1% | |
| Profit Before Tax | 7,346 | 8,995 | 9,187 | 18,193 | 17,274 | 13,319 | 5,287 | -5.3% |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 3 | 0 | |
| Net Profit / (Loss) | 7,414 | 8,995 | 9,187 | 18,193 | 17,274 | 13,316 | 5,287 | -5.5% |
| Net Margin | 18.0% | 14.8% | 17.3% | 22.8% | 20.5% | 18.3% | 13.4% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →